The study of the influence of pharmacotechnological and economic factors on the pharmaceutical development of capsules with trimetazidine for the treatment of cardiovascular diseases

Authors

DOI:

https://doi.org/10.24959/nphj.23.114

Keywords:

capsules; trimetazidine; technology; auxiliary substances; cost

Abstract

Cardiovascular diseases are the main cause of reduced life expectancy and quality in the modern world.

Aim. To study the influence of pharmacotechnological and economic factors on the pharmaceutical development of capsules with trimetazidine for the treatment of cardiovascular diseases.

Materials and methods. The research material was the medicinal substance trimetazidine (SharonBio-Medicine Ltd., India), excipients used in the technology of solid dosage forms.

The study of pharmacotechnological characteristics was carried out on devices of the company “Pharma Test” (Germany). The fluidity and the angle of repose were measured on a VP-12A device. The fluidity was estimated by the Carr Index of powder compressibility and the Hausner Index coefficient. A comparative analysis of the cost calculation of the production of drugs with trimetazidine in tablet and capsulated forms was carried out using the “costs plus” method.

Results and discussion. As a result of the studies conducted on the selection of excipients for capsules with trimetazidine, the following excipients were reasonably used: lactose monohydrate 200/25 diluent, mannitol PARTECK M 200 filler and CompactCel®MAB mixture of a disintegrant, a moisture regulator and a lubricant.

A comparative analysis of the cost calculation of the production of drugs with trimetazidine in tablets and capsules was carried out.

Conclusions. The advantages of direct encapsulation technology by economic and technological indicators prove the economic efficiency and contribute to new developments of high-quality medicinal products in capsules with high efficiency, availability and ease of use.

Author Biographies

V. S. Zlahoda, National Pirogov Memorial Medical University, Vinnytsya

Teaching assistant of the Department of Pharmacy

L. O. Bobrytska, National University of Pharmacy of the Ministry of Health of Ukraine, Kharkiv

Doctor of Pharmacy (Dr. habil.), professor of the Department of Industrial Technology of Drugs

References

Pro zatverdzhennya Unifikovanogo klinichnogo protokolu pervinnoyi, vtorinnoyi (spetsializovanoyi) ta tretinnoyi (visokospetsializovanoyi) medichnoyi dopomogi «Stabilna ishemichna hvoroba sertsya»: Nakaz Ministerstva ohoroni zdorov’ya Ukrayini № 2857 vid 23.12.2021r. Available at.: https://zakon.rada.gov.ua/rada/show/v2857282-21#Text.

Zlagoda, V. S., Bobritska, L. O. (2022). Segmentatsiya suchasnih likarskih form na farmatsevtichnomu rinku Ukrayini. Visnik farmatsiyi, 2 (104), 45-48.

Gladuh, E. V., Ruban, O. A., Sayko, I. V., Chuieshov, V. I., Liapunova, O. O. et al. (2018). Promislova tehnologiya likarskih zasobiv : bazoviy pidruchnik dlya stud. visch. navch. far-mats. zakl. (farmats. f-tiv). 2-e vid., vipr. ta dopov. Kharkiv : NFaU : Noviy Svit-2000, 526 s.

Iqubal, M. K., Singh, P. K., Shuaib, M., Iqubal, A., Singh, M. (2014). Recent advances in direct compression technique for pharmaceutical tablet formulation. IJPRD, 6 (01), 49-57.

Maltais, M., Vargas, R., DiPaolo, T. (2015). Development of a new formulation for di-rect compression of a natural product. Journal of Pharmaceutical Technology & Drug Research., 4 (2), 1-6.

Almaya, A., De Belder, L., Meyer, R., Nagapudi, K., Lin, H. H., Leavesley, I. et al. (2017). Control Strategies for Drug Product Continuous Direct Compressiond State of Control, Prod-uct Collection Strategies, and Startup/Shutdown Operations for the Production of Clinical Trial Mate-rials and Commercial Products. J Pharm Sci., 106 (4), 930-43.

Van Snick, B., Holman, J., Cunningham, C., Kumar, A., Vercruysse, J., De Beer, T. et al. (2017). Continuous direct compression as manufacturing platform for sustained release tablets. International Journal of Pharmaceutics, 519 (1-2), 390-407.

Demchuk, M. B., Groshoviy, T. A., Leskiv, O. M., Malanchuk, N. V. (2021). Porivnyalni doslidzhennya deyakih marok laktozi yak napovnyuvachiv dlya pryamogo presuvannya tabletok. Farmatsevtichniy chasopis, 2, 5-13.

Fares, R., Bobrytska, L., Germanyuk, T., Kryvoviaz, O., Ivko, T., Toziuk, O. et al. (2017). Diaplant: Manufacturing technology and rationalization of costs of acute intestinal infection pharmacotherapy. International Journal of Green Pharmacy, 11 (3), 584-589.

Fares, R., Bobritska, L. O., Shpichak,O. S., Zborovska, T. V., Germanyuk, T. A., Ivko, T. I. et al. (2020). Tehnologichni ta farmakoekonomichni aspekti rozrobki preparatu dlya kom-pleksnoyi terapiyi gostrih kishkovih infektsiy. Upravlinnya, ekonomika ta zabezpechennya yakosti v farmatsiyi, 3 (63), 17-26.

CompactCel®MAB : BIOGRUND EXCiPACT Certification BIOGRUND GmbH. Available at.: https://www.pharma excipients.com/news/.

Downloads

Published

2023-10-23

Issue

Vol. 106 No. 2 (2023)

Section

Technology of Medicines

License

Copyright (c) 2023 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).